Found: 11
Select item for more details and to access through your institution.
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.
- Published in:
- Clinical Infectious Diseases, 2024, v. 78, n. 4, p. 983, doi. 10.1093/cid/ciad506
- By:
- Publication type:
- Article
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial
- Published in:
- Clinical Infectious Diseases, 2021, v. 73, n. 1, p. 33, doi. 10.1093/cid/ciaa822
- By:
- Publication type:
- Article
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus–1: An Integrated Safety Analysis.
- Published in:
- Clinical Infectious Diseases, 2020, v. 70, n. 7, p. 1336, doi. 10.1093/cid/ciz423
- By:
- Publication type:
- Article
Once-daily Doravirine in Human Immunodeficiency Virus Type 1–Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis.
- Published in:
- Clinical Infectious Diseases, 2020, v. 70, n. 7, p. 1344, doi. 10.1093/cid/ciz424
- By:
- Publication type:
- Article
Reply to Lanzafame et al.
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
- Published in:
- Clinical Infectious Diseases, 2019, v. 68, n. 4, p. 535, doi. 10.1093/cid/ciy540
- By:
- Publication type:
- Article
Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002).
- Published in:
- Clinical Infectious Diseases, 2017, v. 65, n. 3, p. 442, doi. 10.1093/cid/cix239
- By:
- Publication type:
- Article
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
An Open-Label Investigation into Drug-Drug Interactions Between Multiple Doses of Daclatasvir and Single-Dose Cyclosporine or Tacrolimus in Healthy Subjects.
- Published in:
- Clinical Drug Investigation, 2015, v. 35, n. 5, p. 281, doi. 10.1007/s40261-015-0279-5
- By:
- Publication type:
- Article
Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone.
- Published in:
- Journal of the International AIDS Society, 2014, v. 17, p. n/a, doi. 10.7448/IAS.17.4.19628
- By:
- Publication type:
- Article
Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2014, v. 69, n. 3, p. 573, doi. 10.1093/jac/dkt412
- By:
- Publication type:
- Article